How to Store Ara 290: Stability and Handling, Per the Research

The short version: two very different evidence categories

ARA-290 (also written Ara-290 or cibinetide) is a short, non-glycosylated synthetic peptide derived from the helix B region of erythropoietin. Because it is a small linear peptide rather than a folded protein drug, questions about its storage fall into two categories that are frequently blurred together:

• Compound-specific published data. Work in which ARA-290 itself was handled, labelled, incubated or measured, and in which the authors reported something about how it behaved.
• General lyophilized-peptide stability science. Principles that apply broadly to short synthetic peptides in freeze-dried or dissolved form, and that have not been demonstrated on ARA-290 in the papers cited here.

Every section below is labelled as one or the other. That distinction matters: a general rule of thumb about peptide solutions is not evidence about this specific sequence, and the published ARA-290 literature is dominated by analytical chemistry and imaging work rather than by formulation or shelf-life studies.

What ARA-290-specific literature exists

The clearest compound-specific handling context comes from radiochemistry. Researchers synthesised and evaluated ^99mTc-DOTA-ARA-290 as a potential SPECT tracer for targeting the cardiac ischemic region, a workflow in which the peptide was conjugated to a chelator, radiolabelled and assessed in aqueous conditions before use (https://pubmed.ncbi.nlm.nih.gov/35317117/). The study is informative less as a shelf-life experiment than as a demonstration that ARA-290 can be chemically modified and carried through wet-chemistry steps while remaining usable as a targeting ligand (https://pubmed.ncbi.nlm.nih.gov/35317117/).

The second relevant body of work is anti-doping analytical chemistry, which deals with peptides under 2 kDa — the size class ARA-290 belongs to. Researchers characterised in vitro generated metabolites of selected peptides below 2 kDa prohibited in sports, work that depends on deliberately incubating peptides under enzymatic conditions to produce and identify fragments (https://pubmed.ncbi.nlm.nih.gov/28941172/). A companion methodological paper simplified and expanded screening for peptides under 2 kDa by direct urine injection, liquid chromatography and ion mobility mass spectrometry (https://pubmed.ncbi.nlm.nih.gov/26578461/). Together these reports show that intact small peptides and their fragments are distinguishable by mass spectrometry in complex matrices (https://pubmed.ncbi.nlm.nih.gov/26578461/).

What none of these three papers provides is a classical stability study: no long-term storage temperature comparison, no accelerated degradation time course for lyophilized ARA-290, and no published shelf-life assignment. That absence is the single most important fact on this page.

Refrigeration: lyophilized versus reconstituted

The dry (lyophilized) state — general peptide science

Freeze-drying removes the water that drives most peptide degradation chemistry. In general peptide science — not ARA-290-specific data — a lyophilized short peptide kept dry, sealed and cold is considered the most stable practical form, because hydrolysis of the peptide backbone, deamidation of asparagine and glutamine residues, and oxidation all proceed far more slowly without bulk water and at reduced temperature. Laboratory certificates of analysis for research-use-only peptide solids commonly specify refrigerated or frozen storage for this reason, and those specifications reflect the manufacturer's own internal testing rather than peer-reviewed publication.

The dissolved (reconstituted) state — general peptide science

Once a lyophilized peptide is dissolved, the chemistry changes completely: water is present, pH becomes a variable, dissolved oxygen is available, and the peptide can adsorb onto container surfaces. General peptide handling practice therefore treats solutions as short-lived relative to the dry solid, with refrigeration used to slow — not stop — degradation. Again, this is a class-level principle; no study in the verified set measured how long ARA-290 remains intact in solution at a given temperature.

The radiotracer work is the closest indirect signal, because researchers necessarily prepared and characterised the DOTA-conjugated peptide in aqueous form before evaluating it as a SPECT tracer for cardiac ischemic tissue (https://pubmed.ncbi.nlm.nih.gov/35317117/). That establishes feasibility of aqueous handling within a working session; it does not establish a storage interval.

Shelf life and expiry: what can and cannot be stated

There is no published, peer-reviewed expiry date for ARA-290 in the papers cited here. Dates that appear on research-use-only labels are assigned by the producing laboratory from its own stability or retest program. In regulatory language, an expiry date on an approved drug product is supported by a documented stability dossier; a "retest date" or "use-by" note on a research chemical is a supplier statement, not an approval. ARA-290 is not an approved drug product in the United States, and material described as research-use-only is by definition not labelled for human use.

The practical consequence for readers of the literature is that any specific shelf-life number encountered for this peptide should be traced to its source — a supplier document, a certificate of analysis, or an unpublished internal test — rather than assumed to come from published research.

Room temperature and transport

Short peptides are routinely shipped as dry powder at ambient temperature, on the general principle that the lyophilized state tolerates brief warm excursions far better than solutions do. This is a class-level convention in peptide chemistry rather than an ARA-290 finding. Factors that general stability science identifies as governing how much an excursion matters include the duration and peak temperature, whether the vial remained sealed, humidity exposure of a hygroscopic powder, and whether the material was dry or already dissolved.

Travel with temperature-sensitive biological material also raises non-chemical issues — customs declarations, carrier rules for cold packs, and the legal status of the material in the destination jurisdiction. Those are regulatory and logistical questions, not stability questions, and nothing in the cited literature addresses them.

Freezing and freeze-thaw

General peptide science treats deep-freezing of the dry solid as the lowest-risk long-term option and repeated freeze-thaw of solutions as a recognised stress. Each cycle exposes a dissolved peptide to ice-front concentration effects, local pH shifts as buffer components crystallise, and mechanical stress at interfaces, all of which are described in the broader protein and peptide formulation field. Aliquoting to avoid repeated cycles is standard laboratory practice for that reason. None of the three verified ARA-290-related papers reported a freeze-thaw experiment on this peptide, so the number of cycles it tolerates is simply unknown from published sources.

Degradation and how it is detected

Visual signals — general, and unreliable

General peptide handling practice notes that a lyophilized cake may change appearance if it absorbs moisture, and that solutions may show cloudiness or particulates if aggregation or precipitation occurs. The important caveat, well established in peptide analytics, is that the most common degradation routes for a short linear peptide — hydrolysis into fragments, deamidation, oxidation of susceptible residues — usually produce no visible change at all. Appearance is therefore a crude screen, not a stability assay.

Analytical detection — what the cited studies actually did

The anti-doping literature illustrates how degradation and fragmentation of small peptides are actually identified. Researchers generated metabolites of selected peptides under 2 kDa in vitro and characterised the resulting fragments analytically, showing that breakdown products of small peptides can be resolved and assigned (https://pubmed.ncbi.nlm.nih.gov/28941172/). On the detection side, the study that simplified and expanded screening for peptides below 2 kDa used direct urine injection with liquid chromatography and ion mobility mass spectrometry, reducing sample preparation while still separating target peptides in a biological matrix (https://pubmed.ncbi.nlm.nih.gov/26578461/). Both reports underline the same point for storage discussions: chromatographic and mass-spectrometric methods, not visual inspection, are what distinguish intact peptide from fragments (https://pubmed.ncbi.nlm.nih.gov/28941172/).

Stability in biological matrices: What Studies Report

Stability in a vial and stability in blood, plasma or urine are different problems. In vitro metabolite work on peptides under 2 kDa showed that enzymatic incubation conditions produce characteristic fragment patterns, which is precisely the behaviour expected of small peptides exposed to peptidases (https://pubmed.ncbi.nlm.nih.gov/28941172/). The urine-screening method paper reported that peptides in this size class could be detected by direct injection of the matrix itself (https://pubmed.ncbi.nlm.nih.gov/26578461/). Separately, the radiotracer study evaluated a DOTA-conjugated ARA-290 construct in the context of cardiac ischemic imaging, where retention of targeting behaviour after chemical modification was the endpoint of interest (https://pubmed.ncbi.nlm.nih.gov/35317117/). None of this constitutes a storage recommendation; it describes how the peptide and its size class behaved under the specific experimental conditions the authors used.

Evidence map: compound-specific versus general

What the literature does not establish

• No published temperature-versus-time stability curve for lyophilized ARA-290.
• No published in-use period for ARA-290 in solution at any temperature.
• No published freeze-thaw tolerance, container-material compatibility or light-sensitivity data for this peptide in the cited papers.
• No approved product labelling to inherit storage conditions from, since ARA-290 is not an approved drug product.

Where a claim about ARA-290 storage is stated with precision — a number of days, a specific temperature window, a cycle count — the source of that precision is worth checking, because the three verified papers here do not supply it.

Educational note

This page is for educational purposes only and is not medical advice; consult a licensed physician or qualified professional for any health question, and treat regulatory and legal status as jurisdiction-specific. Nothing above describes preparation, administration or dosing, and none of the cited studies evaluated storage practices for personal use.

Related reading

• ARA-290: what the research literature covers
• Peptide storage and stability: general principles

References

• Synthesis and evaluation of (99m)Tc-DOTA-ARA-290 as potential SPECT tracer for targeting cardiac ischemic region (Iranian Journal of Basic Medical Sciences, 2021)
• Characterization of in vitro generated metabolites of selected peptides <2 kDa prohibited in sports (Drug Testing and Analysis, 2017)
• Simplifying and expanding the screening for peptides <2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometry (Journal of Separation Science, 2016)